Investor Roadshow Presentation

Botanix has today released an updated corporate presentation to the ASX, to support a non-deal investor roadshow underway this week.

The latest developments in our antimicrobial resistance (AMR) and dermatology R&D programs, include:

  • Progress with our BTX1801 antimicrobial program and plans for Phase 2 clinical studies in early 2022
  • Advancement of our BTX1702 clinical trial for the treatment of rosacea
  • Acceleration of our canine BTX1204A dermatitis study

Click here to view the presentation.

4 replies

Comments are closed.